Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Amon...
Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis
About this item
Full title
Author / Creator
Wang, Zhe , Wang, Xiaoyu , Wang, Zhen , Feng, Yuyi , Jia, Yaqin , Jiang, Lili , Xia, Yangliu , Cao, Jun and Liu, Yong
Publisher
United States: American Medical Association
Journal title
Language
English
Formats
Publication information
Publisher
United States: American Medical Association
Subjects
More information
Scope and Contents
Contents
Although BCR-ABL fusion oncoprotein tyrosine kinase inhibitors (BCR-ABL TKIs) can substantially improve the survival rate of chronic myeloid leukemia (CML), they are clinically accompanied by severe hepatotoxicity.
To compare the relative risk (RR) of hepatotoxicity of new-generation BCR-ABL TKIs with that of imatinib, and to provide an overall...
Alternative Titles
Full title
Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8299317
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8299317
Other Identifiers
ISSN
2574-3805
E-ISSN
2574-3805
DOI
10.1001/jamanetworkopen.2021.20165
